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Abstract
Background: Over 1200 plant species are reported in ethnobotanical studies for the treatment of malaria and
fevers, so it is important to prioritize plants for further development of anti-malarials.
Methods: The “RITAM score” was designed to combine information from systematic literature searches of
published ethnobotanical studies and laboratory pharmacological studies of efficacy and safety, in order to
prioritize plants for further research. It was evaluated by correlating it with the results of clinical trials.
Results and discussion: The laboratory efficacy score correlated with clinical parasite clearance (rs=0.7). The
ethnobotanical component correlated weakly with clinical symptom clearance but not with parasite clearance. The
safety component was difficult to validate as all plants entering clinical trials were generally considered safe, so
there was no clinical data on toxic plants.
Conclusion: The RITAM score (especially the efficacy and safety components) can be used as part of the selection
process for prioritising plants for further research as anti-malarial drug candidates. The validation in this study was
limited by the very small number of available clinical studies, and the heterogeneity of patients included.
Background
Over 1,200 plant species are reportedly used for the treat-
ment of malaria and fevers worldwide, and are potentially
important sources of new anti-malarial treatments [1]. As
there are very limited funds for research on anti-malarial
plants, it is important to prioritize plants for further
research, notably for in depth laboratory studies and
possibly clinical studies. The Research Initiative on
Traditional Anti-malarial Methods (RITAM) was founded
in 1999, and its objectives include to review current knowl-
edge on traditional anti-malarial methods, to determine
research priorities, to design optimal research methodolo-
gies, and to avoid replication of research [2].
Plants widely used as anti-malarials by traditional
healers are significantly more active in vitro and/or in vivo
against Plasmodium sp than plants which are not widely
used, or not used at all, for the treatment of malaria [3-7].
A “retrospective treatment-outcome” study has been pro-
posed to prioritize plants as anti-malarials, by studying
clinical outcomes of patients who have used specified
remedies for treating an episode of malaria [8]. This
approach has proved to work well in Mali [9].
There already exists a wealth of published ethnobotanical
and pharmacological studies on anti-malarial plants. How-
ever, this information has never been reviewed systemati-
cally and there is no standard method for doing so.
Standard scores and methods have been developed for
meta-analysis of studies of medical interventions and diag-
nostic tests [10]. There have been attempts at scoring
plants according to basic ethnobotanical criteria (for exam-
ple frequency of citation, or how widely a remedy is used
[1,6] but these do not take into account all important fac-
tors such as the quality of studies or pharmacological infor-
mation on efficacy and safety. Others have prioritized
plants according to the selectivity index in vitro, corre-
sponding to the ratio between cytotoxicity and activity
against Plasmodium falciparum [11]. The first aim of this
study was to design a standard score that could be used to
prioritize traditional herbal remedies for further research
based on objective criteria and systematic literature
reviews, combining all available information from both
ethnobotanical and pharmacological studies. The second
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dict results of clinical trials for the few plant remedies that
have been tested clinically for the treatment of malaria.
Methods
Design of the score
A “remedy” was defined as a specific preparation from a
specific part of a plant species (for example, Azadirachta
indica A. Juss. (Meliaceae) leaf decoction) or a defined
mixture of parts from one or more plant species. After a
comprehensive literature search, each remedy was given
an overall score, composed of three components:
1: Frequency of citation in ethnobotanical studies
(weighted according to quality of study, as detailed in
Table 1)
2: Efficacy in vitro (Table 2) and in vivo (Table 3)
3: Safety (Tables 4 & 5)
The total score was calculated for each remedy. The
detailed scoring system was drafted and revised by a
multidisciplinary working group including ethnobota-
nists, pharmacologists, phytochemists, clinicians and
epidemiologists.
Ethnobotanical score
This component was designed to take account of all
citations of the remedy for the treatment of malaria or
fever in ethnobotanical studies and historical sources,
weighted by the quality of the studies. If the remedy of
interest was a mixture, only citations of the whole mix-
ture were included in calculating the score (not of indi-
vidual components). However, if the remedy of interest
was a single plant, citations including that plant in a
mixture were included in calculating the score.
Each citation was required to meet the following
inclusion criteria:
1. Citations were preferred from primary ethnobotani-
cal studies (whose quality could be assessed), quoting
original data. Data from reviews or historical documents
(manuscripts, materia medica) were included as long as
the primary source could be identified and did not over-
lap with other citations.
2. The ethnobotanical study was conducted in a
malarious area, or in areas where malaria used to exist
and there remained traditional knowledge of anti-malar-
ial plants.
3. The citation included information on the plant spe-
cies, plant part, and method of preparation used.
The quality of each ethnobotanical citation was
assessed according to the criteria in Table 1. A point
was given for each of the criteria. If the publication
made no mention of a particular criterion, no point was
given for it. For each citation the points were added to a
maximum of 10, and then divided by 10 to give a frac-
tion (for example 10/10 = 1 ; 5/10 = 0.5). This fraction
is the weighted score for the citation. Citations from
reviews and historical sources (for example ancient her-
bals, pharmacopoeias) could not be scored in this same
way, so were given a score of 0.1 for each citation. The
weighted scores of all the citations of a particular
remedy were then added to give the overall ethnobotani-
cal score for that remedy. There was no maximum
score. However if the score was 0 (i.e. the remedy is not
traditionally used) the rest of the scoring system could
not be used.
Laboratory efficacy score
This component was intended to summarize the avail-
able information on efficacy of the remedy from pre-
clinical pharmacological studies in vitro and in vivo.
This scoring was done separately for different extracts,
by plant part, extraction method and solvent used.
Priority was given to extracts which mimicked most
closely the traditional preparation. For example, if a
methanolic extract was more active than an aqueous
decoction, but the decoction was the traditional prepara-
tion, we gave precedence to the score for the decoction.
Table 1 Quality score for ethnobotanical studies
Aspect (max score) Criterion Score
Type of study (2) Primary Ethnobotanical study– original study consulted as source of information +2
OR: Primary ethnobotanical study, quoted in a review, but original data not available +1
Botanical identification (3) Plant collected and verified with informant +1
Voucher specimen in herbarium +1
Formal identification by botanist +1
Name given incorrectly -1
Informant reliability (3) Over 10 informants interviewed +1
>=2 informants mention use of the remedy for malaria +1
Informant(s) have experience of treating malaria +1
Researcher reliability (2) Same language as informants (i.e. information obtained directly without interpreter) +1
Detailed information recorded about remedies +1
TOTAL SCORE (/10) ___/10 =
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tional preparations (e.g. dichloromethane, petroleum
ether) were excluded. If the remedy of interest was a
mixture, only results of laboratory studies of the whole
mixture were included in calculating the score (not of
individual components). For example, for the traditional
remedy Azadirachta indica leaf decoction, the score
would be based on the activity of an aqueous decoction
of A. indica leaf (NOT a methanol or ethanol extract of
the leaves, or the oil from the seeds). Studies were dis-
counted if there was no adequate information on bota-
nical identification of the plant.
When there were several results for one type of
extract, from studies of adequate quality, the score was
given according to the best result (i.e. lowest IC50), as in
table 2. Extra points were available if the activity had
been confirmed in more than one strain of P. falci-
parum with different drug sensitivities and from differ-
ent geographical endemic areas. This score was adapted
from a previous score [12] which had been designed for
assessing fractions rather than crude extracts. Thus the
score has a maximum value of +12 for the in vitro com-
ponent. For the purposes of this review only in vitro
tests on intraerythrocytic parasites were considered, as
the focus was on plants used for treatment (rather than
prevention) of malaria.
If the remedy had also been tested in vivo by the
Peters’ 4-day suppressive test [13] in animal models
(and administered orally), additional points were added
to the efficacy score as in Table 3: one point was given
for each 10% of inhibition. When these components
were added, the maximum possible efficacy score was
+22, and the minimum possible score was –4.
Often extracts are given by the intra-peritoneal route,
and many are efficacious because bioavailability is often
better than by the oral route. However such results were
excluded because the intra-peritoneal route is never used
traditionally and results cannot be applied to oral admin-
istration. Furthermore there is a greater risk of toxicity.
The arbitrary dosage of ≤ 250mg/kg/d was chosen as
an inclusion criterion for the treatment of mice accord-
ing to the Peters’4-day suppressive test. However, many
studies reported either only ED50 (which is the effective
dose reducing the parasitaemia by 50% in comparison
with untreated controls) or tests with other doses from
25 mg/kg/d to 1000 mg/kg/d. Doses of >250mg/kg/d,
which are probably too high to use in practice, did not
score any points. The pharmacological response may
also be affected by the murine Plasmodium species and
strain used in a particular test (chloroquine resistant or
sensitive Plasmodium berghei, Plasmodium vinckei, Plas-
modium yoelii, Plasmodium chabaudi) [14-16].
Safety score (maximum score = +6, minimum = -10)
This component summarized available knowledge on
safety of the remedy. If LD50 (which is the dose lethal
for 50% of the animals) data is available in the literature
f o rs o m er e m e d i e so rp l a n tp a r t s ,t h es c o r ei sg i v e n
according to this (see Table 4). The WHO classification
suggests this should be done in rats, but for the present
score data was used from rats or mice, whichever was
available. If LD50 data was not available, the score in
Table 5 was used to summarize information from any
reports of human toxicity, cytotoxicity tests, and phyto-
chemical analysis.
Overall score
The overall “RITAM score” was the sum of each of the
above components, and was used to rank remedies as a
way of prioritising them for further research. An exam-
ple of how the score was calculated is presented in
Table 6:
Overall RITAM score for a remedy =
Ethnobotanical score (no maximum score)
Table 2 Laboratory efficacy score for in vitro
antiplasmodial activity of crude extracts
IC50 (μg/ml)
(best**)
Score Level of activity
Not tested 0 Needs to be tested (priority to be determined
according to other criteria)
< 2.0 +10* Very good
2.0 - 5.0 +5* Good
This is the concentration range that is generally
considered as active in screening programmes
for anti-malarial activity, warranting bioassay-
guided fractionation.
5.1 - 10 +3* Good to moderate
This range may reasonably be considered for
bioassay-guided fractionation.
11 - 25 +2* Weak
26 - 50 +1 Very weak
>100 -2 Inactive
**Aqueous extracts were priopritized but if these were not available, results
from ethanolic extracts or methanolic extracts were used. Results from non-
polar extracts such as dichloromethane and petroleum ether are too far
removed from traditional preparations and were excluded.
*Add +1 if this level of activity is confirmed in more than one strain of P.
falciparum, from a different continent or with different drug sensitivity, and
+2 if confirmed in 2 or more strains.
Table 3 Laboratory efficacy score for in vivo
antiplasmodial efficacy of crude extracts given to mice at
the dose of 250 mg/kg/day (or lower)
% Inhibition Score Level of activity
Not tested 0
100 - 90 +10 Very good activity
90 - 50 +5-9 Good to moderate
50 - 10 +1-5 Moderate to weak
0 -2 Inactive
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minimum score = -4)
+ Safety score (maximum score = +6, minimum = -10)
The component scores were listed as well as the total,
to enable searching and selection according to different
criteria. For example, natural product chemists may be
less interested in the safetys c o r e ,a sa ni s o l a t e dc o m -
pound may be less toxic or could be modified chemi-
cally to reduce toxicity.
Validating the score
A systematic literature review was conducted of clinical
trials of anti-malarial plants [17]. All published clinical
trials of herbal anti-malarials were identified through sys-
tematic searches of the MEDLINE, EMBASE and CABI
Global Health databases, and by consulting experts for
unpublished data. We then applied the following criteria
to select trials for inclusion in this analysis:
1. A traditional herbal remedy (rather than a modern
combination of traditional plants, for which there would
be no reports in the ethnobotanical literature)
2. Controlled trials or cohort studies including at least
20 patients
3. Parasite clearance at day 7 ascertained by a reliable
method (with two microscopists and/or examining 100
high power fields of a thick film before declaring a film
as negative)
4. Symptom clearance at day 7 reported, and/or Ade-
quate Clinical Response (ACR) at day 14.
However, parasite clearance and symptom clearance
were also included as they are the most often cited in
studies, although they may not be the most appropriate
Table 4 Safety scoring according to LD50
WHO classification Score Acute LD50 for rats (mg/kg body weight)
Oral Dermal
Solid Liquid Solid Liquid
Ia – Extremely hazardous -10 ≤5 ≤20 ≤10 ≤40
Ib – Highly hazardous -8 >5 – 50 >20 – 200 >10 – 100 >40 - 400
II – Moderately hazardous -5 >50 – 500 >200 – 2000 >100 – 1000 >400 - 4000
III – Slightly hazardous -2 >500 – 2000 >2000 – 3000 >1000 – 4000 >4000 - 6000
Unlikely to present acute
hazard
+6 >2000 >3000 >4000 >6000
Not Tested 0
(Source: ANNEX 2: WHO HAZARD CLASSIFICATION - ACUTE LD50 VALUES OF FORMULATED PRODUCTS. In: THE GUIDEBOOK TO THE REGISTRATION OF PUBLIC
HEALTH PESTICIDES AND REPELLENTS AGAINST VECTORS. http://app.nea.gov.sg/cms/htdocs/article.asp?pid=1211).
Table 5 Safety score where LD50 has not been assessed
Safety Score Level of activity
Not evaluated 0 Needs to be tested (priority to be determined according to other
criteria)
Reports of human toxicity +2 Widespread and long-term use in humans with no reported toxicity
-1 Reports of toxicity in humans after ingesting other parts of the same
plant
-2 Reports of mild toxicity in humans after ingesting the relevant plant
part, or a mixture containing this part
ELIMINATE Reports of severe toxicity in humans after ingesting the remedy at a
medicinal dose
Cytotoxicity: Activity Ratio (CAR) in vitro (CAR = IC50 for
cytotoxicity, divided by IC50 for anti-malarial activity)
+10 ≥1000
+5 1000 > CAR≥100
+2 100 > CAR≥ 50
+1 50 > CAR≥ 10
0 10 > CAR >= 2
-5 CAR <2
Toxic chemical constituents +2 Plant chemistry studied in depth, and no known toxic compounds
have been found.
-1 Toxic compounds found in a different plant part, or likely to be
destroyed or evaporated in preparation of the remedy
-3 Toxic compounds found in the relevant plant part, which are not
likely to be destroyed in preparation
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mended by the RITAM guidelines [18], based on WHO
guidelines [19]. Incidence and severity of side-effects
were also assessed as important secondary outcomes.
ACR is defined as absence of parasitaemia on day 14
irrespective of axillary temperature, without previously
meeting any of the criteria of early or late treatment fail-
ure; or axillary temperature <37.5°C irrespective of the
presence of parasitaemia, without previously meeting
any of the criteria of early or late treatment failure.
Early treatment failure is defined as development of
danger signs on day 1, 2 or 3 in the presence of parasi-
taemia; or axillary temperature ≥37.5Â°C on day 2 with
parasitaemia > day 0 count; or axillary temp ≥37.5Â°C
on day 3 with parasitaemia. WHO guidelines also count
afebrile patients with parasitaemia on day 3 ≥25% of
count on day 0 as early treatment failures, but these are
not included in the modified RITAM definition. Late
treatment failure is defined as development of any dan-
ger signs or signs of severe malaria, or axillary tempera-
ture ≥37.5Â°C, in the presence of parasitaemia on any
day from day 4 to day 14, without previously meeting
any of the criteria of early treatment failure.
For the same remedies, the RITAM score was calcu-
lated following a systematic literature search of the
same databases for ethnobotanical and pharmacological
studies of anti-malarial plants. Experts were also con-
tacted for other sources of ethnobotanical and pharma-
cological studies. Over 100 ethnobotanical studies and
52 pharmacological studies, as well as existing literature
reviews were consulted [20].
Spearman rank correlation coefficients (rs) [21] were
calculated for correlation between RITAM scores and
clinical outcomes (see Table 7). The Kendall partial
rank correlation coefficient [21] was used to adjust for
the age of the patients included in the studies.
Table 6 Calculation of the RITAM score for Vernonia
amygdalina leaf decoction
Component of
Score
Parameter Value Reference Score
Ethnobotanical Citation scores (see table1for
details of calculation)
[40] 0.5
[41] 0.6
[42] 0.9
[43] 0.6
[44] 0.6
[45] 0.5
[46] 0.5
[47] 0.8
Efficacy IC50 in vitro 76.7 µg/ml [48] 0
% inhibition
in vivo
62.7% [49] 6
Safety LD50 3320mg/kg [50] 6
TOTAL 17
Table 7 RITAM Scores compared to results of good quality clinical trials in uncomplicated falciparum malaria
Remedy RITAM score Clinical results Study characteristics Ref
Overall Ethnobotanical Efficacy Safety Parasite
clearance
d7 (%)
Fever
clearance
d7 (%)
Side
effects
(%)
ACR
d14
(%)
No f
patients
Mean
age
(yrs)
Geometric
mean
parasitaemia
d0
Artemisia annua
L. (Asteraceae)
aerial parts
infusion
19.9 0.9 13 6 74% 86% 72 [27]
Vernonia
amygdalina
Delile
(Asteraceae) leaf
decoction
17.0 5.0 6 6 32% 67% 65% 67% 33 29 5393 [28]
Argemone
mexicana L.
(Papaveraceae)
leaf decoction
14.9 1.9 7 6 21% 74% 17% 73% 231 10 1746 [35,51]*
Cochlospermum
planchonii Hook.
f. ex Planch.
(Bixaceae) root
decoction
6.0 2.0 1 3 52% 62% 46% 46 23 11191 [29]
Combretum
micranthum G.
Don
(Combretaceae)
mixtures
0.5 0.5 0 0 14% 79% 13% 28% 78 4 3874 [32]
*Data from these two studies were pooled for the analysis.
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patients aged 12 years and over with baseline parasite
counts of 500 per µl and over, which in one case
involved re-analysis of the raw data (see Table 8).
Results
Ten herbal remedies were identified that have under-
gone clinical trials published in the literature, meeting
our inclusion criteria. Trials of only three remedies
included “adequate clinical response” as an outcome, so
it was not possible to calculate the correlation between
RITAM scores and this outcome. The quality of the clini-
cal trials was variable; in particular five trials did not spe-
cify the methodology for ascertaining parasite clearance.
These are likely to overestimate parasite clearance, so
they were eliminated from further statistical analysis. The
trials excluded for this reason were those of Caesalpinia
crista (Fabaceae) seed powder [22], Cinchona (Rubiaceae)
bark extract [23], Dichroa febrifuga (Hydrangeaceae) root
decoction [24], Cochlospermum tinctorium (Bixaceae)
root decoction [25], and Cryptolepis sanguinolenta
(Apocynaceae) root infusion [26].
The five trials using adequate methods for measuring
parasite clearance are shown in Table 7. Spearman rank
correlation identified that parasite clearance was corre-
lated with the efficacy score (rs = 0.6) and with average
age of the patients (rs = 0.7). The analysis was then stra-
tified according to age. There were too few studies of
children under five years to permit any meaningful ana-
lysis in this age group. Data was available from four stu-
dies (or subsets thereof) of patients aged 12 years and
above [27-30], although only two of these used ACR as
an outcome measure. In this subset parasite clearance
correlated better with the efficacy score (rs =0 . 7 ) .T h e
ethnobotanical score did not correlate with parasite
clearance (rs = 0), but there was a slight correlation with
symptom clearance (rs = 0.5). Too few clinical studies
reported on the incidence of side-effects to be able to
c a l c u l a t eac o r r e l a t i o nw i t ht h es a f e t ys c o r e .A l m o s ta l l
of the plants selected in this validation had a high safety
score, as would be expected. None of the trials reported
any serious adverse effects.
Discussion
This is a first attempt to devise and pilot a scoring sys-
tem to prioritize anti-malarial herbal remedies for
further research, based on existing ethnobotanical data,
and laboratory data on efficacy and safety. The overall
score for most promising remedies was over 14, showing
good results in all domains. However combining the
scores can also have disadvantages. Cinchona (which is
highly effective, and the source of quinine, which can be
toxic [31]) scored 6.5 overall (ethnobotanical = 3.5; effi-
cacy = 8; safety = -5) which was the same score as the
safe but ineffective topical Shea butter (ethnobotanical =
0.5; efficacy = 0; safety = 6) [32].
The evaluation of the proposed RITAM score is lim-
ited by the paucity of good quality published clinical
trials of herbal anti-malarials. Despite an exhaustive lit-
erature search, clinical trials of only ten remedies were
identified, only five of which had used good quality
methods for evaluating parasite clearance, and only
three of which had recorded ACR as an outcome. Even
in some of these the preparation and dose may not have
been optimal.
Definition of clinical outcome is of central importance
to this evaluation. Prevention of severe malaria is in fact
the desired effect, and can be achieved without total para-
site clearance [30,33], but large numbers of patients are
needed in order to detect differences in this outcome, so it
is not commonly used. ACR was devised as a surrogate
measure but its definition is complex, and may be inter-
preted slightly differently in different studies [34]. Parasite
clearance is a simpler outcome which should have the
Table 8 Sensitivity analysis including only patients aged >12 years with baseline parasitaemia of >500 per mcl
Remedy RITAM score Clinical results Study characteristics Refes
Overall Ethnobotanical Efficacy Safety Parasite
clearance
d7 (%)
Symptom
clearance
d7 (%)
Side
effects (%)
ACR
d14 (%)
No f
patients
Baseline
parasitaemia
(gm)
Artemisia annua
aerial parts
infusion
19.9 0.9 13 6 74% 86% 72 [27]
Vernonia
amygdalina leaf
decoction
17.0 5.0 6 6 32% 67% 65% 67% 33 5393 [28]
Argemone
mexicana leaf
decoction
14.9 1.9 7 6 50% 88% 13% 94% 16 3162 [30]*
Cochlospermum
planchonii root
decoction
6.0 1.0 2 3 52% 62% 46% 46 11191 [29]
*Subgroup analysis including only patients with the defined characteristics.
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debatable in high transmission areas where reinfection
occurs rapidly [33]. Several clinical studies reported signifi-
cant declines in parasite counts although total clearance
was not achieved [25,35]. The accurate assessment of
parasite clearance requires high quality methods, which is
why clinical studies not reporting such methods were
excluded. Almost all of the trials reported symptom clear-
ance in 60% or more of the patients, which suggests that
traditional medicines are at least effective at relieving
symptoms. The definition of “symptom clearance” also
varied between studies so the figures reported are not
necessarily comparable. Similarly, methods for ascertaining
side-effects varied between trials, so the incidence figures
are not comparable between trials. A checklist of possible
side-effects [28] will inevitably generate a higher incidence
of reports than asking an open question about side-effects,
which was used in some other studies [35]. Some of the
symptoms reported may well have been due to the disease
rather than to the treatment [29]. In some of the clinical
studies it is not clear whether patients were even asked
about possible side-effects.
Clinical recovery and parasite clearance depend not
only on the efficacy of the remedy but also on the level of
immunity of the patient. All of the clinical studies took
place in areas of intense seasonal transmission in sub-
Saharan Africa, although the transmission season may
have been shorter in the area where Bugmann’ss t u d y
took place, so levels of immunity may have been lower
there [32]. Age is one of the major confounders and
explains at least some of the differences between the stu-
dies. Several studies included only patients above the age
of 12 [28,29] or 18 [27] and these tended to have better
parasite clearance and adequate clinical response rates
than the studies including younger children [30,32,35].
The correlation of the laboratory efficacy score with
parasite clearance suggests that pre-clinical studies are
useful predictors of clinical efficacy. There may be a pub-
lication bias because poor results are less likely to be
published. However neither in vitro nor in vivo tests pre-
dicted all clinically useful remedies. Vernonia amygdalina
(Asteraceae) had low in vitro activity but good in vivo
activity (table 6). Argemone mexicana (Papaveraceae) did
not show any activity in animals, although there was
clear evidence of activity in vitro and in humans [30].
A better correlation might be obtained by testing the
anti-malarial activity in vitro of the serum of healthy
volunteers having ingested the remedy [36], but this
method has not been widely used. This would avert the
problem of contaminating compounds such as saponins
that complicate traditional testing of extracts in vitro.
The ethnobotanical score did not correlate with parasite
clearance, but did correlate weakly with symptom clear-
ance. This supports the view that traditional healers select
plants which act on the symptoms, although not necessa-
rily on the underlying cause of the disease. One limitation
of the score is that for some plants the bulk of the ethno-
botanical information is in documents which are unpub-
lished or which are not included in international
databases. A case in point is Artemisia annua (Asteraceae)
which had the highest efficacy score and the best parasite
clearance, but for which there is almost no ethnobotanical
information in the international literature, so it had a very
low ethnobotanical score. It was selected by the Chinese
because of information in traditional Chinese texts, which
are not catalogued in standard international databases. In
fact another species (A. apiacea Hance) was used prefer-
entially in ancient Chinese medicine, but it has never
undergone clinical trials [37]. Inclusion of national and
local databases (especially Chinese) may improve the valid-
ity of the ethnobotanical score, but in practice this is diffi-
cult to do. Another concern is the influence of geographic
range on the ethnobotanical score. Plants with a small
geographic distribution do not have the opportunity to be
cited in many studies. Cryptolepis sanguinolenta is one
such plant, which is reported only in Ghana and in the
Congo, but with a strong local reputation. Strong ethno-
medical evidence, such as from a retrospective treatment-
outcome study [8,38], is probably a better predictor of
efficacy than the number of citations. A revised score
might take into account how extensively the plant is used
across its distribution in malarious regions.
The safety component of the score was difficult to evalu-
ate as few clinical trials contained quantitative information
on incidence of side-effects, and furthermore clinical trials
would only be done on plants which are well known to be
non-toxic. The remedy with the lowest safety score (-5)
was Cinchona bark, because of the reports of mild side-
effects from use in humans [31], and because it contains
potentially toxic alkaloids (including quinine). However,
the clinical trials report that the incidence of side-effects
from the bark was no greater than with the use of pure
quinine [31]. Therefore the presence of toxic compounds
should perhaps be given less weight because toxicity
always depends on dose and many effective medicines are
toxic when excessive doses are given. The safety score is
important to ensure toxic remedies are filtered out and
not taken forward into clinical research, but there is a risk
that it may screen out some of the most effective remedies
that are toxic only at doses higher than the therapeutic
dose, or have only mild and usually tolerable side-effects
(such as Cinchona). For this reason it may be preferable to
use a therapeutic index obtained in vivo by the ratio LD50/
ED50. It is possible that a highly active plant would also be
highly toxic, and so may receive a positive overall score.
H o w e v e ri ti sv e r yu n l i k e l yt h a ta ne x t r e m e l yh a z a r d o u s
plant would survive the test of time as a traditional medi-
cine (or indeed that those taking it would survive or
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Page 7 of 9encourage others to use it), and this score is only intended
for plants which are used as traditional medicines.
Although it was not possible to validate the safety compo-
nent of the score, safety is a very important consideration
for prioritization of plants. In the absence of anything bet-
ter we suggest that the safety score should be used as part
of the selection process for prioritizing plants.
Another drawback of the score is that it is difficult to
evaluate complex remedies which contain several plants.
Most ethnobotanical studiesr e p o r to nu s e so fs i n g l e
plants rather than combinations, so that the ethnobota-
nical score would be low for such remedies. It is also
rare for such combination remedies to be tested as such
in vitro and in vivo. The only exception we found was
“Malarial”, a combination of three plants used in Mali,
which had undergone preclinical parasitological and
safety tests prior to clinical trials and registration as an
“improved traditional medicine” [39].
Although this scoring system was developed specifically
to prioritize anti-malarial plants, it could be modified as a
way of prioritizing plants for clinical trials on other dis-
eases, although it would need to be validated again using
relevant trials. The ethnobotanical component might be
expected to be useful for diseases which are easily recog-
nized traditionally, for example intestinal worms, dysen-
tery, and skin ulcers. It would not be useful for diseases
which have been newly discovered or which cannot be
diagnosed without modern medical equipment (such as
HIV/AIDS or Chagas disease). The efficacy component
could however be adapted for any disease for which
laboratory models exist, as a way of prioritising among
many plants tested. The safety component could be
applicable for any remedy (although we must stress that
this part of the score could not be validated in our study).
Conclusions
The overall RITAM score can be used as part of the selec-
tion process for prioritizing anti-malarial plants for future
research, alongside other factors such as ease of cultivation
and preparation. In particular the laboratory efficacy com-
ponent of the score correlated with parasite clearance in
good quality clinical trials, and so can be used as one way
to prioritize and rationalize the selection of herbal reme-
dies for future clinical studies. The ethnobotanical score
was not useful because the score was low for plants whose
u s ei sm a i n l yr e p o r t e di nt r a d i tional texts, which cannot
easily be accessed from modern databases, and for plants
whose distribution is localized. The safety score is impor-
tant but we were unable to evaluate this fully because all
of the plants taken into clinical trials and published were
relatively non-toxic. The validation in this study was lim-
ited by the very small number of available clinical studies,
and the heterogeneity of included patients. More clinical
studies of herbal anti-malarials are needed, and as these
become available it should be possible to improve the
scoring system and its validation.
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